MCID: IDP011
MIFTS: 55

Idiopathic Interstitial Pneumonia

Categories: Respiratory diseases

Aliases & Classifications for Idiopathic Interstitial Pneumonia

MalaCards integrated aliases for Idiopathic Interstitial Pneumonia:

Name: Idiopathic Interstitial Pneumonia 12 14
Pulmonary Fibrosis 42 69
Idiopathic Interstitial Pneumonia, Not Otherwise Specified 69
Diffuse Idiopathic Pulmonary Fibrosis 12
Idiopathic Interstitial Pneumonias 69
Idiopathic Fibrosing Alveolitis 12
Hamman-Rich Syndrome 69
Ipf 12

Classifications:



Summaries for Idiopathic Interstitial Pneumonia

Disease Ontology : 12 A pneumonia located in the lung parenchyma of unknown cause.

MalaCards based summary : Idiopathic Interstitial Pneumonia, also known as pulmonary fibrosis, is related to acute interstitial pneumonia and nonspecific interstitial pneumonia, and has symptoms including coughing, hemoptysis and snoring. An important gene associated with Idiopathic Interstitial Pneumonia is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Bosentan and Nintedanib have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 72 Idiopathic interstitial pneumonia (IIP), or noninfectious pneumonia are a class of diffuse lung... more...

Related Diseases for Idiopathic Interstitial Pneumonia

Diseases related to Idiopathic Interstitial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
id Related Disease Score Top Affiliating Genes
1 acute interstitial pneumonia 31.6 ICAM1 IFNG IL4 TLR9
2 nonspecific interstitial pneumonia 11.9
3 interstitial lung disease 11.3
4 airway-centered interstitial fibrosis 11.1
5 pulmonary fibrosis, idiopathic 11.0
6 lymphoid interstitial pneumonia 11.0
7 interstitial pneumonitis, desquamative, familial 11.0
8 cryptogenic organizing pneumonia 11.0
9 myoclonic astatic epilepsy 10.9 IFNG IL4
10 anonychia with flexural pigmentation 10.8 SFTPA1 SFTPC
11 cholesteatoma of middle ear 10.8 IFNG IL13 TGFB1
12 goat milk allergy 10.8 IFNG IL13 IL4
13 eye accommodation disease 10.7 IFNG IL4
14 acute gonococcal prostatitis 10.7 IFNG IL13 IL4
15 pneumonia 10.7
16 acute necrotizing encephalopathy type 1 10.7 IFNG IL13 TLR9
17 sublingual gland cancer 10.7 IL13 IL4 TLR9
18 tularemia 10.7 IFNG IL4 TLR9
19 dieulafoy lesion 10.6 IFNG IL4 TLR9
20 balkan nephropathy 10.6 IFNG IL13 IL4
21 malignant neoplasm of acoustic nerve 10.6 SFTPA1 SFTPA2 SFTPD
22 plantar wart 10.6 CXCL8 IFNG TGFB1
23 epidermolysis bullosa simplex superficialis 10.6 CTGF IL4 TGFB1
24 motor peripheral neuropathy 10.6 IFNG IL4 TLR9
25 testicular infarct 10.6 CXCL8 MUC5B TLR9
26 conjunctival concretion 10.6 CXCL8 IL13 TGFB1
27 dissociated nystagmus 10.6 IL4 SFTPA2 SFTPD
28 uterus interstitial leiomyoma 10.6 IFNG IL13 IL4
29 uterine inflammatory disease 10.6 EDN1 SERPINE1
30 opportunistic bacterial infectious disease 10.6 IFNG IL4 TLR9
31 esophagus melanoma 10.6 CXCL8 IFNG IL4
32 neurotrophic keratoconjunctivitis 10.6 CCL2 SFTPC SFTPD
33 myofascial pain syndrome 10.6 CCL2 CXCL8 IL13
34 ostertagiasis 10.6 CCL2 IL4 TLR9
35 malignant hyperthermia 10.6 IFNG IL4 TLR9
36 hypervitaminosis d 10.5 IFNG IL4 TLR9
37 hypertrichosis of eyelid 10.5 CCL2 CTGF TGFB1
38 status epilepticus 10.5 CCL2 IFNG IL4
39 dengue disease 10.5 IFNG IL13 IL4 TLR9
40 exudative vitreoretinopathy 1 10.5 CCL2 CTGF TGFB1
41 lymphoma 10.5 IFNG IL13 IL4 TLR9
42 chronic inflammatory demyelinating polyradiculoneuropathy 10.5 CCL2 CTGF TGFB1
43 mediastinum neurofibroma 10.5 IFNG IL13 IL4 TLR9
44 lacrimal system cancer 10.5 IFNG IL13 IL4 TLR9
45 early-onset zonular cataract 10.5 IFNG IL4 VEGFA
46 blue toe syndrome 10.5 CXCL8 IFNG IL4
47 steatorrhea 10.5 CCL2 CXCL8 IFNG
48 nephrotic syndrome, idiopathic, steroid-resistant 10.5 CTGF EDN1 TGFB1
49 pneumoconiosis 10.5 CCL2 CXCL8 IFNG
50 pasteurellosis 10.5 CXCL8 EDN1 IFNG

Comorbidity relations with Idiopathic Interstitial Pneumonia via Phenotypic Disease Network (PDN): (show all 22)


Acute Cystitis Bronchiectasis
Bronchitis Bronchopneumonia
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hypothyroidism Intermediate Coronary Syndrome
Ischemic Heart Disease Left Ventricular Outflow Tract Obstruction
Mitral Valve Disease Osteoporosis
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Pulmonary Hypertension, Familial Primary, 1, with or Without Hht Respiratory Failure
Rheumatoid Arthritis Rheumatoid Lung Disease

Graphical network of the top 20 diseases related to Idiopathic Interstitial Pneumonia:



Diseases related to Idiopathic Interstitial Pneumonia

Symptoms & Phenotypes for Idiopathic Interstitial Pneumonia

UMLS symptoms related to Idiopathic Interstitial Pneumonia:


coughing, hemoptysis, snoring

MGI Mouse Phenotypes related to Idiopathic Interstitial Pneumonia:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 SFTPA1 SFTPD TGFB1 TLR9 VEGFA CTGF
2 growth/size/body region MP:0005378 10.32 SFTPC SFTPD TGFB1 VEGFA CTGF EDN1
3 immune system MP:0005387 10.28 TGFB1 TLR9 VEGFA CCL2 ELANE ICAM1
4 hematopoietic system MP:0005397 10.27 ELANE ICAM1 IFNG IL13 IL4 MUC5B
5 cellular MP:0005384 10.26 ICAM1 IFNG IL13 IL4 MUC5B PTPRC
6 mortality/aging MP:0010768 10.25 CTGF EDN1 ELANE GREM1 ICAM1 IFNG
7 digestive/alimentary MP:0005381 10.21 IL4 PTPRC TGFB1 TLR9 VEGFA CTGF
8 endocrine/exocrine gland MP:0005379 10.1 EDN1 ICAM1 IFNG IL13 IL4 PTPRC
9 neoplasm MP:0002006 9.86 ELANE ICAM1 IFNG PTPRC SERPINE1 SFTPC
10 liver/biliary system MP:0005370 9.85 IFNG IL4 PTPRC SERPINE1 TGFB1 VEGFA
11 renal/urinary system MP:0005367 9.81 EDN1 GREM1 IFNG IL4 PTPRC SERPINE1
12 respiratory system MP:0005388 9.77 CTGF GREM1 IFNG IL13 IL4 MUC5B
13 skeleton MP:0005390 9.28 CTGF EDN1 GREM1 IFNG IL13 IL4

Drugs & Therapeutics for Idiopathic Interstitial Pneumonia

Drugs for Idiopathic Interstitial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2 147536-97-8 104865
2
Nintedanib Approved Phase 4,Phase 3,Phase 2 656247-17-5 56843413
3
Pirfenidone Investigational Phase 4,Phase 3,Phase 2,Phase 1 53179-13-8 40632
4 Phosphodiesterase 5 Inhibitors Phase 4,Phase 2,Phase 3
5 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3
6 Sildenafil Citrate Phase 4,Phase 2,Phase 3 171599-83-0
7 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1
8 Antihypertensive Agents Phase 4,Phase 3,Phase 2
9 Endothelin Receptor Antagonists Phase 4,Phase 3,Phase 2
10 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
11 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Citrate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
17
Citric Acid Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 77-92-9 311
18
Sulfamethoxazole Approved Phase 3 723-46-6 5329
19
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
20
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
21
Treprostinil Approved, Investigational Phase 3,Phase 2 81846-19-7 54786 6918140
22
Iloprost Approved, Investigational Phase 2, Phase 3 78919-13-8 6443959
23
Acetylcysteine Approved, Investigational Phase 3,Phase 2,Phase 1 616-91-1 12035
24
Azathioprine Approved Phase 3,Phase 1,Phase 2 446-86-6 2265
25
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
26
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
27
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
28
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
29
Losartan Approved Phase 2, Phase 3 114798-26-4 3961
30
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
31
Mycophenolic acid Approved Phase 3 24280-93-1 446541
32
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
33
Lenograstim Approved Phase 3 135968-09-1
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
36
Warfarin Approved Phase 3 81-81-2 6691 54678486
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
39
Angiotensin II Investigational Phase 2, Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
40 Anti-Bacterial Agents Phase 3,Phase 2
41 Anti-Infective Agents Phase 3,Phase 2,Phase 1
42 Antimalarials Phase 3,Phase 2
43 Antiparasitic Agents Phase 3,Phase 2
44 Antiprotozoal Agents Phase 3,Phase 2
45 Cytochrome P-450 Enzyme Inhibitors Phase 3
46 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
47 Renal Agents Phase 3
48 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
49 Vitamin B Complex Phase 3,Phase 2,Phase 1
50 Platelet Aggregation Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 280)

id Name Status NCT ID Phase Drugs
1 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Unknown status NCT00625079 Phase 4 sildenafil;sildenafil
2 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Unknown status NCT00625469 Phase 4 bosentan
3 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
4 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
5 Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT02598193 Phase 4 Nintedanib;Pirfenidone
6 Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF Completed NCT02579603 Phase 4 Nintedanib;Pirfenidone
7 A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination Completed NCT02606877 Phase 4 nintedanib;pirfenidone
8 Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment Active, not recruiting NCT02788474 Phase 4 nintedanib;placebo
9 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
10 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis Terminated NCT01321996 Phase 4
11 Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole Unknown status NCT01777737 Phase 3 Cotrimoxazole;Placebo
12 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
13 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension Unknown status NCT00705133 Phase 3 treprostinil
14 Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Unknown status NCT00439543 Phase 2, Phase 3 Iloprost inhalation
15 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00600028 Phase 3 Thalidomide;Placebo
16 Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 Completed NCT00631475 Phase 3 Bosentan
17 Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
18 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01366209 Phase 3 Pirfenidone;Placebo
19 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287716 Phase 3 Pirfenidone;Placebo
20 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287729 Phase 3 Pirfenidone;Placebo
21 Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
22 Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Completed NCT00981747 Phase 2, Phase 3 Sildenafil;Losartan;Sildenafil and Losartan;Placebo pill
23 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis Completed NCT00517933 Phase 3 Sildenafil Citrate
24 Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00662038 Phase 3 pirfenidone
25 A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00047645 Phase 3 Interferon-gamma 1b
26 Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00639496 Phase 3 n-acetylcysteine;placebo
27 BUILD 3: Bosentan Use in Interstitial Lung Disease Completed NCT00391443 Phase 3 Bosentan;Placebo
28 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients Completed NCT01335464 Phase 3 placebo;BIBF 1120
29 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II Completed NCT01335477 Phase 3 placebo;BIBF 1120
30 Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization Completed NCT02584816 Phase 3
31 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Completed NCT00650091 Phase 3 N-acetylcysteine (NAC);Placebo
32 A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients Completed NCT01014442 Phase 3 mycophenolate mofetil
33 Rituximab in Rheumatoid Arthritis Lung Disease Completed NCT00578565 Phase 3 Rituximab
34 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
35 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Completed NCT00105183 Phase 3
36 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
37 Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis Recruiting NCT02739165 Phase 3 ART-123;Placebo
38 Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). Recruiting NCT03208933 Phase 3 Pirfenidone
39 Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Recruiting NCT02460588 Phase 3 Cyclophosphamide;Placebo;Corticosteroid (prednisolone)
40 Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment Recruiting NCT02802345 Phase 3 Nintedanib;Placebo;Sildenafil
41 Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea Recruiting NCT03018756 Phase 3 Fentanyl Citrate;Placebo
42 CleanUP IPF for the Pulmonary Trials Cooperative Recruiting NCT02759120 Phase 3 Antimicrobial therapy: Co-trimoxazole or Doxycycline
43 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Recruiting NCT02597933 Phase 3 Nintedanib;Placebo
44 Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis Active, not recruiting NCT01619085 Phase 3 BIBF 1120
45 Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis Not yet recruiting NCT03068234 Phase 2, Phase 3 Pirfenidone;Placebo oral capsule;Steroids
46 ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis Terminated NCT00879229 Phase 3 Ambrisentan;Placebo
47 AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Terminated NCT00957242 Phase 3 warfarin;placebo
48 Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) Terminated NCT01979952 Phase 3 Matching Placebo;Nintedanib
49 (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF Terminated NCT00768300 Phase 3 Ambrisentan;Placebo
50 The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) Terminated NCT00075998 Phase 3 Interferon gamma-1b ("Actimmune")

Search NIH Clinical Center for Idiopathic Interstitial Pneumonia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: pulmonary fibrosis

Genetic Tests for Idiopathic Interstitial Pneumonia

Anatomical Context for Idiopathic Interstitial Pneumonia

MalaCards organs/tissues related to Idiopathic Interstitial Pneumonia:

39
Lung, Testes, Heart, Liver, Skin, Endothelial, Bone

Publications for Idiopathic Interstitial Pneumonia

Articles related to Idiopathic Interstitial Pneumonia:

(show top 50) (show all 144)
id Title Authors Year
1
Impact of lymphocyte differential counta88>a8815% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. ( 28427425 )
2017
2
Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. ( 28300570 )
2017
3
Respiratory bronchiolitis-associated interstitial lung disease - an unexpected form of idiopathic interstitial pneumonia in a young male. ( 28523329 )
2017
4
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. ( 28838377 )
2017
5
Occupational and Environmental Risk Factors for Chronic Fibrosing idiopathic Interstitial Pneumonia in South Korea. ( 28938261 )
2017
6
Baseline serum syndecan-4 predicts prognosis after the onset of acute exacerbation of idiopathic interstitial pneumonia. ( 28467516 )
2017
7
Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. ( 26699835 )
2016
8
Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis. ( 27564852 )
2016
9
Idiopathic pleuroparenchymal fibroelastosis - A rare idiopathic interstitial pneumonia. ( 27141432 )
2016
10
Increased erythrocyte aggregation and oxidative stress in patients with idiopathic interstitial pneumonia. ( 28079842 )
2016
11
A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia. ( 26932342 )
2016
12
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. ( 26792595 )
2016
13
Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? ( 27884593 )
2016
14
Postoperative pyothorax a risk factor for acute exacerbation of idiopathic interstitial pneumonia following lung cancer resection. ( 27277761 )
2016
15
The pathological features of idiopathic interstitial pneumonia-associated pulmonary adenocarcinomas. ( 27757985 )
2016
16
Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias. ( 26873743 )
2016
17
Identification of Clinical Phenotypes in Idiopathic Interstitial Pneumonia with Pulmonary Emphysema. ( 27301501 )
2016
18
Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. ( 26792177 )
2016
19
Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. ( 27266705 )
2016
20
Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. ( 27460223 )
2016
21
Idiopathic pleuroparenchymal fibroelastosis, a new idiopathic interstitial pneumonia: A case report. ( 26810762 )
2016
22
Symptom-based management of the idiopathic interstitial pneumonia. ( 26450007 )
2015
23
Idiopathic interstitial pneumonia in the ICU: an observational cohort. ( 26603794 )
2015
24
Scoring of the radiological picture of idiopathic interstitial pneumonia: a study to verify the reliability of the method. ( 26600944 )
2015
25
Exercise pathophysiology and the role of oxygen therapy in idiopathic interstitial pneumonia. ( 26416262 )
2015
26
Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia. ( 26116477 )
2015
27
Broader criteria of undifferentiated connective tissue disease in idiopathic interstitial pneumonias. ( 25682542 )
2015
28
The correlation of symptoms, pulmonary function tests and exercise testing with high-resolution computed tomography in patients with idiopathic interstitial pneumonia in a tertiary care hospital in South India. ( 26664164 )
2015
29
Evolving Early Lung Cancers Detected During Follow-Up of Idiopathic Interstitial Pneumonia: Serial CT Features. ( 26001227 )
2015
30
Newly Detected Pulmonary Nontuberculous Mycobacterial Infection and Peripheral Lung Cancers in Patients During Follow-Up of Idiopathic Interstitial Pneumonia: Comparison of CT Findings. ( 25837763 )
2015
31
Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs. ( 26539479 )
2015
32
SFTPA2 Mutations in Familial and Sporadic Idiopathic Interstitial Pneumonia. ( 26568241 )
2015
33
Smoking-related idiopathic interstitial pneumonia: A review. ( 26138798 )
2015
34
Role of I+1 and I+2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts. ( 26006016 )
2015
35
Increased ectodomain shedding of cell adhesion molecule 1 as a cause of type II alveolar epithelial cell apoptosis in patients with idiopathic interstitial pneumonia. ( 26231557 )
2015
36
Smoking-related idiopathic interstitial pneumonia. ( 25063244 )
2014
37
Low-normal lung volume correlates with pulmonary hypertension in fibrotic idiopathic interstitial pneumonia: computer-aided 3D quantitative analysis of chest CT. ( 25055292 )
2014
38
Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia. ( 24388373 )
2014
39
Expression of toll-like receptor 2 and 4 is increased in the respiratory epithelial cells of chronic idiopathic interstitial pneumonia patients. ( 24613046 )
2014
40
The pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study. ( 24586445 )
2014
41
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. ( 24937643 )
2014
42
Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability. ( 24886036 )
2014
43
Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. ( 24033388 )
2014
44
Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: similarity and difference. ( 24480141 )
2014
45
Limitations to the 6-minute walk test in dermatomyositis with interstitial lung disease in comparison with idiopathic interstitial pneumonia. ( 23400027 )
2013
46
Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. ( 23928896 )
2013
47
Immunohistochemical detection of virus through its nuclear cytopathic effect in idiopathic interstitial pneumonia other than acute exacerbation. ( 24270907 )
2013
48
Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. ( 23678265 )
2013
49
MMP-7 and fcDNA Serum Levels in Early NSCLC and Idiopathic Interstitial Pneumonia: Preliminary Study. ( 24336111 )
2013
50
High-resolution CT scan findings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia. ( 23364926 )
2012

Variations for Idiopathic Interstitial Pneumonia

Expression for Idiopathic Interstitial Pneumonia

Search GEO for disease gene expression data for Idiopathic Interstitial Pneumonia.

Pathways for Idiopathic Interstitial Pneumonia

Pathways related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CCL2 CXCL8 ELANE ICAM1 IFNG IL13
2
Show member pathways
13.56 CCL2 CTGF CXCL8 ICAM1 IFNG IL13
3
Show member pathways
13.38 CCL2 CXCL8 ICAM1 IFNG IL13 IL4
4
Show member pathways
13.31 CCL2 CTGF CXCL8 IL13 IL4 PTPRC
5
Show member pathways
13 CCL2 CXCL8 EDN1 MUC5B SERPINE1 TLR9
6
Show member pathways
12.84 CXCL8 ICAM1 IFNG IL13 IL4 TGFB1
7
Show member pathways
12.81 CCL2 CXCL8 IFNG SERPINE1 SFTPA2 SFTPD
8
Show member pathways
12.78 CCL2 CXCL8 ICAM1 IFNG IL13 IL4
9 12.56 CCL2 IFNG IL4 PTPRC TLR9
10
Show member pathways
12.32 CCL2 CXCL8 IFNG IL13 IL4 MUC5B
11 12.2 IFNG TGFB1 TLR9 VEGFA
12
Show member pathways
12.16 CXCL8 IFNG IL13 IL4
13
Show member pathways
12.15 CXCL8 IFNG IL4 SFTPA1 SFTPD TLR9
14 12.09 CCL2 ICAM1 SERPINE1 TLR9
15 12.08 CCL2 EDN1 ICAM1 IFNG VEGFA
16 11.96 CXCL8 IFNG SERPINE1 TGFB1
17 11.96 CCL2 CXCL8 ICAM1 IFNG IL4 TGFB1
18 11.92 EDN1 IFNG SERPINE1 VEGFA
19
Show member pathways
11.91 IFNG IL4 TGFB1 TLR9
20
Show member pathways
11.89 SFTPA1 SFTPA2 SFTPC SFTPD
21 11.86 CCL2 CXCL8 ICAM1 IL13 IL4 TGFB1
22 11.83 CCL2 GREM1 TGFB1
23 11.8 IFNG IL13 IL4 PTPRC
24 11.79 CXCL8 ICAM1 IFNG IL13 IL4
25 11.77 IFNG PTPRC TGFB1 TLR9
26
Show member pathways
11.76 CXCL8 IFNG IL4
27 11.76 CXCL8 SFTPA1 SFTPA2
28 11.75 CCL2 CXCL8 ICAM1 IFNG TGFB1 VEGFA
29 11.73 ICAM1 IL4 TGFB1 TLR9
30 11.69 EDN1 SERPINE1 VEGFA
31
Show member pathways
11.68 CXCL8 ICAM1 IFNG VEGFA
32 11.63 IFNG SERPINE1 TGFB1
33 11.57 CXCL8 TGFB1 VEGFA
34 11.54 CTGF ELANE ICAM1
35
Show member pathways
11.52 SFTPA1 SFTPA2 SFTPD
36 11.52 IFNG IL13 IL4
37 11.5 CCL2 CXCL8 EDN1 ICAM1 SERPINE1 TGFB1
38 11.49 CXCL8 ICAM1 IFNG
39
Show member pathways
11.46 SFTPA1 SFTPA2 SFTPC SFTPD
40 11.46 CCL2 CXCL8 ICAM1 IL13 IL4
41 11.4 EDN1 SERPINE1 VEGFA
42 11.37 ICAM1 IFNG TLR9
43 11.32 IFNG IL13 IL4
44 11.32 CCL2 CXCL8 ICAM1 IFNG TGFB1 TLR9
45 11.27 IFNG IL13 IL4 TGFB1
46 11.26 IFNG IL13 TGFB1
47 11.23 CCL2 CXCL8 IL13 IL4
48 11.22 IFNG IL13 IL4
49 11.2 CCL2 CTGF CXCL8 EDN1 GREM1 IL13
50 11.19 CCL2 ICAM1 IFNG

GO Terms for Idiopathic Interstitial Pneumonia

Cellular components related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 CCL2 CTGF CXCL8 EDN1 ELANE GREM1
2 cell surface GO:0009986 9.88 ELANE GREM1 ICAM1 PTPRC TGFB1 VEGFA
3 proteinaceous extracellular matrix GO:0005578 9.87 CTGF SFTPA1 SFTPA2 SFTPD TGFB1 TLR9
4 external side of plasma membrane GO:0009897 9.77 ICAM1 IFNG IL13 IL4 PTPRC
5 platelet alpha granule lumen GO:0031093 9.61 SERPINE1 TGFB1 VEGFA
6 extracellular space GO:0005615 9.6 CCL2 CTGF CXCL8 EDN1 ELANE GREM1
7 clathrin-coated endocytic vesicle GO:0045334 9.56 SFTPA1 SFTPA2 SFTPC SFTPD
8 lamellar body GO:0042599 9.46 SFTPA1 SFTPA2 SFTPC SFTPD

Biological processes related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 CCL2 CTGF ICAM1 TGFB1
2 response to drug GO:0042493 9.99 CCL2 EDN1 ICAM1 IFNG IL4 TGFB1
3 response to lipopolysaccharide GO:0032496 9.97 CCL2 EDN1 ELANE ICAM1 IL13
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 GREM1 ICAM1 TGFB1 TLR9
5 response to organic cyclic compound GO:0014070 9.94 CTGF ICAM1 IL4 TGFB1
6 cellular response to tumor necrosis factor GO:0071356 9.93 CCL2 CXCL8 EDN1 ICAM1
7 positive regulation of angiogenesis GO:0045766 9.92 CXCL8 GREM1 SERPINE1 VEGFA
8 response to hypoxia GO:0001666 9.92 CCL2 EDN1 ICAM1 TGFB1 VEGFA
9 response to ethanol GO:0045471 9.91 CCL2 ICAM1 IL13 IL4
10 movement of cell or subcellular component GO:0006928 9.9 CXCL8 IFNG IL13
11 response to wounding GO:0009611 9.89 CCL2 CTGF TGFB1
12 positive regulation of protein phosphorylation GO:0001934 9.89 CTGF IFNG IL4 TGFB1 VEGFA
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 ICAM1 IL4 TGFB1 VEGFA
14 positive regulation of T cell proliferation GO:0042102 9.87 IFNG IL4 PTPRC
15 cellular response to interferon-gamma GO:0071346 9.86 CCL2 EDN1 ICAM1
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 EDN1 ELANE IL13
17 cellular response to interleukin-1 GO:0071347 9.86 CCL2 CXCL8 EDN1 ICAM1
18 positive regulation of tumor necrosis factor production GO:0032760 9.85 CCL2 IFNG TLR9
19 neutrophil chemotaxis GO:0030593 9.85 CCL2 CXCL8 EDN1 IFNG
20 positive regulation of cell adhesion GO:0045785 9.84 CCL2 IFNG VEGFA
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 EDN1 ICAM1 IFNG
22 cellular response to lipopolysaccharide GO:0071222 9.83 CCL2 CXCL8 ICAM1 IFNG SERPINE1
23 cellular response to dexamethasone stimulus GO:0071549 9.81 CCL2 ICAM1 TGFB1
24 positive regulation of MAP kinase activity GO:0043406 9.78 EDN1 ELANE TGFB1 VEGFA
25 positive regulation of collagen biosynthetic process GO:0032967 9.77 CCL2 CTGF TGFB1
26 positive regulation of protein complex assembly GO:0031334 9.77 IFNG TGFB1 VEGFA
27 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.75 GREM1 TGFB1 VEGFA
28 PERK-mediated unfolded protein response GO:0036499 9.73 CCL2 CXCL8
29 angiogenesis GO:0001525 9.73 CCL2 CTGF CXCL8 GREM1 SERPINE1 VEGFA
30 leukocyte migration involved in inflammatory response GO:0002523 9.72 CCL2 ELANE
31 positive regulation of mast cell degranulation GO:0043306 9.72 IL13 IL4
32 negative regulation of interleukin-17 production GO:0032700 9.72 IFNG TGFB1
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IFNG IL4
34 positive regulation of chemokine biosynthetic process GO:0045080 9.71 IFNG IL4
35 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 IFNG IL4 VEGFA
36 maternal process involved in parturition GO:0060137 9.7 CCL2 EDN1
37 surfactant homeostasis GO:0043129 9.7 SFTPD VEGFA
38 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IFNG IL4
39 acute inflammatory response to antigenic stimulus GO:0002438 9.68 ELANE ICAM1
40 positive regulation of cellular extravasation GO:0002693 9.67 CCL2 ICAM1
41 toll-like receptor signaling pathway GO:0002224 9.67 SFTPA1 SFTPA2 SFTPD TLR9
42 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.66 GREM1 VEGFA
43 positive regulation of odontogenesis GO:0042482 9.65 EDN1 TGFB1
44 regulation of proton transport GO:0010155 9.65 IL13 IL4
45 positive regulation of mononuclear cell migration GO:0071677 9.64 IL4 TGFB1
46 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL13 IL4
47 positive regulation of B cell proliferation GO:0030890 9.5 IL13 IL4 PTPRC
48 response to amino acid GO:0043200 9.46 CCL2 CTGF EDN1 ICAM1
49 positive regulation of immunoglobulin production GO:0002639 9.4 IL13 IL4
50 negative regulation of endothelial cell apoptotic process GO:2000352 9.26 ICAM1 IL13 IL4 SERPINE1

Molecular functions related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 CTGF IL4 TGFB1 VEGFA
2 cytokine activity GO:0005125 9.28 CCL2 CXCL8 EDN1 GREM1 IFNG IL13
3 vascular endothelial growth factor receptor 2 binding GO:0043184 9.26 GREM1 VEGFA
4 heparin binding GO:0008201 9.26 CCL2 CTGF ELANE VEGFA

Sources for Idiopathic Interstitial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....